Cannabis and ADHD — evidence and risk

For ADHD there is insufficient evidence of cannabis efficacy or safety (Cooper 2017: RCT n=30 showed no significant benefit). Regular use worsens attention, working memory and executive function (Broyd 2016). First-line care is methylphenidate/lisdexamfetamine + behavioural therapy. Cannabis dependence rate is 1.5–3× higher among people with ADHD (Lee 2011).

TL;DR

  • Small RCT (Cooper 2017, n=30): Sativex, no significant QbTest effect.
  • Self-reports: short-term focus, long-term executive-function decline.
  • ADHD + cannabis: 3× risk of cannabis use disorder.
  • First line remains stimulants (Ritalin, Vyvanse) + behavioural therapy.

Why the 'calm' is misleading

THC dampens prefrontal activity — hence the calm, but working memory and impulse control acutely worsen (Broyd 2016). The very functions already deficient in ADHD.

Neurobiological Mechanisms and the Dopamine Paradox

The neurobiological basis of attention deficit hyperactivity disorder (ADHD) is closely linked to altered regulation of dopamine metabolism in the prefrontal cortex. Those affected often exhibit underactivity in these brain regions, leading to chronic restlessness and distractibility. The intake of tetrahydrocannabinol (THC) can lead to an increased release of dopamine in the short term. This explains why many affected individuals perceive a subjective calming and an apparent improvement in their focus. However, this temporary relief masks the underlying cognitive deficits and frequently leads to a misjudgment of the actual therapeutic effect.

In the long term, however, regular cannabis use leads to a noticeable desensitisation of the body's own dopamine system. The density of cannabinoid receptors decreases, further restricting the brain's capacity for self-regulation. Instead of providing sustainable relief for ADHD symptoms, chronic use exacerbates executive dysfunctions such as planning ability and impulse control. The initial relief thus turns into a worsening of the core symptoms, which massively reinforces the vicious cycle of self-medication and the risk of dependence.

  • Short-term dopamine release creates the illusion of a therapeutic effect
  • Long-term downregulation of dopamine receptors worsens symptoms
  • Impairment of the already weakened executive functions in the prefrontal cortex
  • Increased risk of a vicious circle due to subjective but harmful self-medication

Swiss legal situation and medical prescribing practice

Since the amendment of the law in August 2022, medical cannabis can be prescribed directly by doctors in Switzerland without an exceptional permit from the Federal Office of Public Health (BAG). For patients with ADHD, this theoretically represents an option if established first-line therapies such as methylphenidate fail or cause severe side effects. However, since the scientific evidence for its efficacy in ADHD is extremely low, such a prescription is only issued after a strict case-by-case assessment as an off-label therapy. As a rule, the costs are not covered by the compulsory health insurance.

A key aspect of daily life in Switzerland is the strict zero-tolerance practice in road traffic. Regardless of whether cannabis is used as legal medication or for recreational consumption, a statutory THC limit of 1.5 micrograms per litre of blood applies. Anyone exceeding this limit is deemed unfit to drive. Since THC and its metabolites remain detectable in the body for a long time, people with ADHD risk the permanent revocation of their driving licence if they consume it regularly. Furthermore, the consumption of illegal THC cannabis (over one percent total THC) in public spaces remains a punishable offence.

  • Medical cannabis directly prescribable by doctors since August 2022
  • Prescription for ADHD only as an off-label therapy with very little scientific support
  • Strict limit in road traffic of 1.5 micrograms of THC per litre of blood
  • Cost coverage by health insurance companies only occurs in rare exceptional cases

Differential diagnosis and the risk of comorbidities

ADHD rarely occurs in isolation; a large proportion of those affected suffer from comorbid disorders such as anxiety, depression or severe sleep disorders. Many patients turn to cannabis primarily to alleviate these distressing accompanying symptoms. If consumption makes it easier to fall asleep or temporarily dampens inner tension, this is falsely interpreted as a therapeutic success for the overall ADHD symptoms. However, the actual core symptoms, such as inattention and lack of impulse control, remain unaffected or even worsen in the medium term.

In addition, the regular consumption of high-potency THC carries the risk of worsening psychological comorbidities in the long term. Instead of relieving anxiety, cannabis can intensify it or even trigger panic attacks. In adolescents and young adults with ADHD, the brain is still developing, which is why consumption has been proven to increase the risk of developing psychoses and persistent depressive episodes. A sound psychiatric assessment is therefore essential in order to differentiate and evaluate the interactions between ADHD, comorbidities and cannabis use.

  • Frequent use for self-medication of accompanying symptoms such as sleep disorders
  • Apparent relief of anxiety masks the deterioration of cognitive performance
  • Increased risk of worsening depression and anxiety due to THC
  • Risk of psychosis in vulnerable individuals, particularly during brain development

FAQ

Can CBD help with ADHD?

No positive RCTs in ADHD. Occasionally useful for comorbid anxiety or insomnia.

Does CBD oil help with ADHD symptoms?

Unlike THC, CBD (cannabidiol) has no intoxicating effect and does not directly intervene in the dopamine system. Scientific evidence for a direct efficacy of CBD on core ADHD symptoms such as inattention or hyperactivity is still largely lacking. However, there are indications that CBD can provide support in managing accompanying symptoms such as internal tension or sleep problems. Since CBD products with a total THC content of less than one percent are legal in Switzerland, some of those affected use them as a supplement, which, however, cannot replace professional therapy.

Can I obtain a prescription for medical cannabis in Switzerland despite an ADHD diagnosis?

Yes, since August 2022, doctors in Switzerland have been able to prescribe medical cannabis directly. However, as there is insufficient scientific evidence for ADHD, this is an off-label use. A prescription is usually only considered if established therapies such as stimulants or psychotherapy show no effect or cause intolerable side effects. The decision is at the discretion of the treating specialist, and the costs must generally be borne by the patient, unless the health insurance company approves a cost assumption in individual cases.

How does cannabis affect the efficacy of Ritalin or other ADHD medications?

Combining cannabis with stimulants such as methylphenidate or lisdexamfetamine carries unpredictable risks. While stimulants increase activity in the prefrontal cortex to improve concentration, THC dampens these areas. The substances thus counteract each other, neutralizing the therapeutic effect of the medication. In addition, the combination can place a heavy strain on the cardiovascular system, as both substances can affect heart rate and blood pressure. From a medical perspective, co-consumption is therefore strongly discouraged.